Abstract
Novel rifamycins such as ABI-0043, ABI-0369, and ABI-0699 had comparable in vivo bactericidal activity with ceftriaxone against a penicillin-G-resistant, mefA-positive Streptococcus pneumoniae in a murine pneumonia model. ABI-0043 demonstrated a dose-dependent response with a high correlation to bacterial kill (+0.1 to −3.7 log10CFU).
Similar content being viewed by others
Article PDF
References
Musher DM . Streptococcus pneumoniae. In: Mandell G, et al. (eds). Principles and Practice of Infectious Diseases, 5th ed. Churchill Livingstone, New York, pp. 2128–2147 ( 2000)
Jernigan DB, Cetron MS, Breiman RF . Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group. JAMA 275: 206–209 ( 1996)
Gordon KA, Biedenbach DJ, Jones RN . Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 46: 285–289 ( 2003)
Murphy CK, Mullin S, Osburne MS, Duzer J, Siedlecki J, et al. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 50: 827–834 ( 2006)
Mullin S, Rothstein DM, Murphy CK . Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes. Antimicrob Agents Chemother 50: 1908–1909 ( 2006)
Rothstein DM, Farquhar RS, Sirokman K, Sondergaard KL, Hazlett C, et al. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection. Antimicrob Agents Chemother 50: 3658–3664 ( 2006)
Farquhar R, Xia M, Meerts I, Phillips L, Buxton D, Larsson M, Chen Y, Murphy CK, Macneil I . Activity of novel rifamycins in assays for human cytochrome P450 induction. Abstracts of Papers of 45th Intersci Conf on Antimicrob Agents Chemother, F-2048, Washington, DC ( 2005)
Tessier PR, Kim MK, Zhou W, Xuan D, Li C, Ye M, Nightingale CH, Nicolau DP . Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 46: 1425–1434 ( 2002)
Mattoes HM, Banevicius MA, Li D, Turley C, Xuan D, Nightingale CH, Nicolau DP . Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrob Agents Chemother 45: 2092–2097 ( 2001)
Capitano B, Maglio D, Banevicius MA, Nightingale CH, Nicolau DP . Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model. Intern J Antimicrob Agents 22: 588–593 ( 2003)
Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibilities tests for bacteria that grow aerobically-Fifteenth Informational Supplement. CLSI/NCCLS document M100-S15. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA. ( 2005)
Institute of Laboratory Animal Research: Guide for the care and use of laboratory animals. National Academy Press, Washington DC
Andes D, Craig WA . In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 42: 2375–2379 ( 1998)
Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C . Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the post-antibiotic effect of imipenem. Antimicrob Agents Chemother 41: 345–351 ( 1997)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, S., Tessier, P., Murphy, C. et al. Bactericidal Efficacy of ABI-0043, a Novel Rifamycin, in a Murine Pneumococcal Pneumonia Model. J Antibiot 59, 804–807 (2006). https://doi.org/10.1038/ja.2006.107
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ja.2006.107